Healthcare

Abu Dhabi to host AstraZeneca-Oracle AI health-data program

The Abu Dhabi component of the AstraZeneca-Oracle partnership will use AI and health data to improve hypertension management and clinical research recruitment.

The first operational project under AstraZeneca and Oracle’s new AI partnership will be deployed in Abu Dhabi with healthcare company M42. It will focus on hypertension care and clinical research, using AI and real-world data to identify patients whose blood pressure remains uncontrolled. The initiative is also intended to support guideline-directed treatment and improve recruitment for clinical trials. The project illustrates how healthcare AI is being positioned as a bridge between population-level data, clinical decision support, and research operations. It is distinct from the partnership announcement because the Abu Dhabi program represents the concrete regional application described by the source. Hypertension is being used as the initial clinical area, while the wider collaboration is expected to cover oncology, cardiovascular, renal and metabolic, respiratory, immunology, and rare diseases. The source does not report patient outcomes, regulatory approval, or the precise AI systems that will be used. It does establish that the initiative is designed for coordinated implementation across care and research settings, making it a notable GCC development in data-enabled disease management and trial recruitment.

Original source: MarketScreener

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI